Get the Stockscreener App
19.27
8.75%
1.55
Zai Lab Limited Adr stock is traded at $19.27, with a volume of 920.70K.
It is up +8.75% in the last 24 hours and up +13.35% over the past month.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
See More
Previous Close:
$17.72
Open:
$18.28
24h Volume:
920.70K
Relative Volume:
1.17
Market Cap:
$2.16B
Revenue:
$418.33M
Net Income/Loss:
$-252.07M
P/E Ratio:
-8.0292
EPS:
-2.4
Net Cash Flow:
$-238.84M
1W Performance:
-0.62%
1M Performance:
+13.35%
6M Performance:
-35.77%
1Y Performance:
-43.32%
1-Day Range:
$18.09
$19.59
1-Week Range:
$17.10
$20.04
52-Week Range:
$15.96
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Name
Zai Lab Limited Adr
Sector
Industry
Phone
862161632588
Address
899 HALEI ROAD, SHANGHAI
Compare ZLAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
19.27 | 1.99B | 418.33M | -252.07M | -238.84M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-14-23 | Initiated | Morgan Stanley | Overweight |
| Aug-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-22 | Initiated | Macquarie | Outperform |
| Oct-12-21 | Initiated | Bernstein | Mkt Perform |
| Apr-28-20 | Initiated | Goldman | Buy |
| Apr-15-20 | Initiated | Guggenheim | Buy |
| Jul-12-19 | Initiated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
| Jan-29-19 | Initiated | Credit Suisse | Outperform |
| Nov-21-18 | Initiated | Jefferies | Buy |
| Jun-21-18 | Resumed | Leerink Partners | Outperform |
| Feb-14-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Initiated | JP Morgan | Neutral |
| Oct-16-17 | Initiated | Leerink Partners | Outperform |
View All
Zai Lab Limited Adr Stock (ZLAB) Latest News
Zai Lab (NASDAQ:ZLAB) Shares Up 9.3%Should You Buy? - MarketBeat
[144] Zai Lab Ltd SEC Filing - Stock Titan
Affiliate sale: ZLAB (NASDAQ: ZLAB) files to sell 10,000 ADS - Stock Titan
Cantor Fitzgerald Lowers Zai Lab (NASDAQ:ZLAB) Price Target to $37.00 - Defense World
Zai Lab Q4 Earnings Call Highlights - Yahoo Finance
Zai Lab Limited 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ZLAB) 2026-02-27 - Seeking Alpha
Zai Lab (NasdaqGM:ZLAB) Loss Per Share Narrows To US$1.60 And Tests Bearish Narratives - Sahm
Zai Lab (NASDAQ:ZLAB) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Zai Lab Limited (ZLAB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Zai Lab Ltd SEC 10-K Report - TradingView
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - ChartMill
Zai Lab: Q4 Earnings Insights - Sahm
An Overview of Zai Lab's Earnings - Sahm
Zai Lab (ZLAB) Expected to Announce Earnings on Thursday - MarketBeat
Zai Lab Stock Pops on U.S. FDA Progress: Is Wall Street Still Too Bearish? - AD HOC NEWS
Zai Lab (NASDAQ:ZLAB) Shares Gap Up – Here’s What Happened - Defense World
Qiming funds disclose 4.4% Zai Lab (ZLAB) stake in amended 13G/A - Stock Titan
Zai Lab (NASDAQ:ZLAB) Shares Gap UpHere's Why - MarketBeat
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $51.59 Consensus Price Target from Analysts - Defense World
Constellation Software Inc. (OTCMKTS:CNSWF) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Analysts Set Kraken Robotics Inc. (CVE:PNG) PT at C$7.13 - Defense World
Brokerages Set Whirlpool Corporation (NYSE:WHR) Target Price at $85.43 - Defense World
Everus Construction Group, Inc. (NYSE:ECG) Receives $102.75 Average PT from Brokerages - Defense World
FY2026 Earnings Forecast for PACCAR Issued By Zacks Research - Defense World
Plexus Corp. (NASDAQ:PLXS) Receives $189.20 Average Target Price from Analysts - Defense World
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) PT at $14.50 - Defense World
Brokerages Set Medical Properties Trust, Inc. (NYSE:MPW) Price Target at $6.17 - Defense World
Zai Lab Limited's (NASDAQ:ZLAB) Shift From Loss To Profit - Yahoo Finance
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026 - Business Wire
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Wellington Group reports 4.3% Zai Lab (ZLAB) stake on amended 13G - Stock Titan
JPMorgan Chase & Co. Has Lowered Expectations for Zai Lab (NASDAQ:ZLAB) Stock Price - MarketBeat
$207B Market Shift: The Race for Fast Track Approval in Oncology - Benzinga
$207B Market Shift: The Race for Fast Track Approval in Oncology - Sahm
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Benzinga
Hilton Food Group (LON:HFG) Insider Purchases £198,900 in Stock - Defense World
Zai Lab (NASDAQ:ZLAB) Reaches New 1-Year Low – Time to Sell? - Defense World
Is UBS’s Global-Innovation Framing Rewriting Zai Lab’s (ZLAB) Long-Term Biopharma Platform Narrative? - Sahm
UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform - Finviz
Zai Lab (NASDAQ:ZLAB) Sets New 12-Month LowHere's Why - MarketBeat
8 High Growth Chinese Stocks To Buy - Insider Monkey
Zai Lab Limited (ZLAB) Stock Analysis: Eyeing a 169% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Zai Lab (NASDAQ:ZLAB) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Short Interest in AiRWA Inc. (NASDAQ:YYAI) Rises By 24.6% - Defense World
Short Interest in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Drops By 19.8% - MarketBeat
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Update - Defense World
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After New AUGTYRO Approval And Pipeline Progress - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Animalcare Group (LON:ANCR) Stock Passes Below 200-Day Moving Average – Here’s What Happened - Defense World
How Investors May Respond To Zai Lab (ZLAB) Winning Expanded China Approval For AUGTYRO Cancer Therapy - Sahm
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
Zai Lab Limited Adr Stock (ZLAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):